TargetMol

Reboxetine mesylate

Product Code:
 
TAR-T6963
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6963-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6963-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6963-10mg10mg£129.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6963-25mg25mg£203.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6963-50mg50mg£316.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6963-100mg100mg£462.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6963-500mg500mg£922.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Reboxetine is a norepinephrine reuptake inhibitor (Ki: 8.2 nM).
CAS:
98769-84-7
Formula:
C19H23NO3?CH4O3S
Molecular Weight:
409.5
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9964
SMILES:
c1cc(c(cc1)O[C@@H]([C@@H]1OCCNC1)c1ccccc1)OCC.S(=O)(=O)(C)O
Target:
Adrenergic Receptor; Norepinephrine

References

Rauhut AS, et al. J Pharmacol Exp Ther, 2002, 303(2), 664-672. Versiani M, et al. J Clin Psychiatry, 2002, 63(1), 31-37. Wong EH, et al. Biol Psychiatry, 2000, 47(9), 818-829. Versiani M, et al. J Clin Psychiatry, 1999, 60(6), 400-406. Page ME, et al. Neuropsychopharmacology, 2002, 27(2), 237-247.